Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced risk of developing Alzheimer's disease-related dementia among patients with type 2 diabetes, a recent study reported.A new study published in the Journal of Alzheimer's Disease analyzed the medical records of over 1.7 million U.S. adults and found that semaglutide users experienced a notably lower risk of dementia compared to patients treated with insulin, metformin, or older GLP-1 agonists.These findings, publicly released on Tuesday, come as researchers and clinicians continue to search for effective means to mitigate the growing dementia epidemic in the U.S.Why It MattersWith over 6 million Americans diagnosed with dementia and more than 100,000 related deaths each year, the potential for semaglutide to meaningfully lower risk could have sweeping public health implications.Dementia does not have a cure, and nearly half of all cases are thought to be preventable by addressing risk factors like obesity, type 2 diabetes, and cardiovascular disease, the New York Post reported.Evidence supporting semaglutide's neuroprotective effects may inform future prevention strategies among high-risk populations in the U.S.What To KnowLandmark Study Shows Sharp Risk ReductionResearchers at Case Western Reserve School of Medicine, National Institutes of Health and the MetroHealth System in Cleveland examined the health records of 1,710,995 U.S. patients with type 2 diabetes who had no prior diagnosis of Alzheimer's disease-related dementia (ADRD).The study used a statistical method simulating a randomized clinical trial, comparing dementia diagnoses among those prescribed semaglutide, insulin, metformin, and older GLP-1 receptor agonists.Patients treated with semaglutide had a 46 percent lower risk of developing ADRD than those receiving insulin, a 33 percent lower risk than those on metformin, and a 20 percent lower risk than those on earlier GLP-1 agonists. The effect was particularly pronounced for vascular dementia, one of the most common subtypes.No protective association was found for frontotemporal dementia or Lewy body dementia.Wide Demographic Impact ObservedThe protective association was consistent among subgroups, including younger and older patients, men and women, and those with and without obesity.Researchers found the risk reduction was especially evident among older adults and women.What is Semaglutide?Semaglutide is a glucagon-like peptide-1 receptor agonist that helps regulate blood sugar, lowers body weight, and offers cardiovascular benefits for patients with diabetes.The drug can help improve insulin sensitivity, protect blood vessels, and reduce inflammation in the brain.Important Study LimitationsAuthors acknowledged limitations, including reliance on administrative diagnosis codes, which are subject to underdiagnosis and misclassification, data on medication adherence, cognitive test scores, and genetic risk factors were unavailable. Variations in clinical practice and health care use variations could also affect findings.Researchers emphasized the need for preclinical and clinical studies to establish causal effects.Additional International DataA separate study by Oxford University, published in Lancet's eClinicalMedicine journal, analyzed more than 100 million U.S. medical records and found that Ozempic users experienced lower rates of cognitive decline and nicotine use compared to those on other diabetes medications.This study also did not find a higher risk of anxiety, depression, or other neurological and psychiatric conditions with Ozempic. The researchers emphasized that the results were limited to diabetic patients and require more rigorous randomized controlled trials.What People Are SayingThe researchers of the study, in a news article published by the American Journal of Managed Care: "In a real-world population with T2D [type 2 diabetes] who had no prior diagnosis of AD/ADRD [Alzheimer disease/Alzheimer disease-related dementia], our study shows that semaglutide was associated with a significantly lower risk of overall ADRD incidence compared with other antidiabetic medications, including insulin, metformin, and other GLP-1RAs. Significant reductions were observed in older and younger patients, women and men, and patients with and without obesity."Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, in comments to Reuters: "The answer to all those limitations is to do a randomized clinical trial, which is exactly what Novo is doing."What Happens NextNovo Nordisk, the maker of Ozempic, began testing semaglutide in patients with early Alzheimer's disease in 2021. The results are expected sometime this year.Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@newsweek.com.